HCP21

HEALTH CONNECT PARTNERS

agenda

live! ONLINE nashville
2021 SPRING CONFERENCE

Hospital Pharmacy

April 12–May 6, 2021

BD

titlesponsor

BD

titlesponsor

VIRTUAL supplier**showcase** sponsor

VIRTUAL supplier**showcase**

OPEN DURING THE ENTIRE CONFERENCE

Health Connect Partners' Virtual Supplier Showcase provides a format for hospital decision makers to research, learn about, and connect with suppliers in a unique virtual space. Each virtual booth features the supplier organization and highlights their solutions, products, and technologies. This platform is designed to give hospital providers and supplier organizations the ability to directly interact in a customized environment.

In addition to providing the platform, Health Connect Partners is focused on driving high-quality traffic to each Virtual Supplier Showcase booth—just like we do during our in-person Supplier Showcase events. The Virtual Supplier Showcase is open for visits any time during the conference dates and is a required stop on the way to the educational sessions. Each provider executive will be encouraged to participate in a fun, interactive virtual experience allowing them to learn and request information along their journey through the Virtual Supplier Showcase. The more booths they check in at, the more entries they will have in the prize drawing.

Best of all:
the Virtual Supplier Showcase platform allows provider executives to directly request information, and schedule meetings with suppliers through our virtual meeting platform. Providers have a choice of requesting a meeting during the Virtual Reverse Expo or selecting a specific date and time for an on-demand meeting outside of the Virtual Reverse Expo times.

To maximize this experience for everyone, only Providers and Supplier attendees from companies with a Virtual Showcase will be able to access the showcase area.

BD

titlesponsor

ON-DEMAND
educationalsessions

Monday April 12th
8:00am CT All Educational Sessions Released

Tuesday April 13th
Live Q&A for Educational Session Two
11:00am–11:15am CT & 5:00pm–5:15pm CT

Wednesday April 14th
Live Q&A for Educational Session Three
11:00am–11:15am CT & 5:00pm–5:15pm CT

Thursday April 15th
Live Q&A for Educational Session Four
11:00am–11:15am CT & 5:00pm–5:15pm CT

Monday April 19th
Live Q&A for Educational Session Five
11:00am–11:15am CT & 5:00pm–5:15pm CT

Tuesday April 20th
Live Q&A for Educational Session Six
11:00am–11:15am CT & 5:00pm–5:15pm CT

Wednesday April 21st
Live Q&A for Educational Session Seven
11:00am–11:15am CT & 5:00pm–5:15pm CT

Thursday April 22nd
Live Q&A for Educational Session Eight
11:00am–11:15am CT & 5:00pm–5:15pm CT

*Each Educational Session is available to view **ON-DEMAND** any time from 8:00am CT on April 12th until 10:59pm CT on May 21st.*

CE CREDIT DETAILS
All educational sessions will be released at 8:00am Central on Monday, April 12th, and will be available for on-demand viewing, until Friday, May 21st.

Please be aware that if you want to obtain LIVE CE credit for a session, you must watch the session AND participate in a Live Q&A at either 11:00am Central or at 5:00pm Central on the date specified for each session. Live Q&As are not available on-demand. *If you do not participate in the Live Q&A and also watch the session, you will only be eligible to receive Enduring CE credit for each session you view.*

Each session will be available for on-demand viewing (and Enduring CE) until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As will be available for Sessions 2-8.

Your CE credit will be posted to your CPE Monitor account by June 4th.

Live Inspired

John O'Leary
In 1987, John O'Leary was a curious nine-year-old boy. Playing with fire and gasoline, John created a massive explosion in his home and was burned on 100% of his body. He was given less than a 1% chance to live.

This epic story of survival was first showcased in his parents' book, *Overwhelming Odds*, in 2006. Originally printing 200 copies for friends and family, his parents have sold 60,000+ copies. It was this book that first invited John to embrace his miraculous recovery and share it with the world.

John inspires 50,000+ people at 100+ events each year. He speaks to companies and organizations across industries, such as: sales, healthcare, safety, marketing, finance, faith, education and insurance.

Consistently described as "the best speaker we've ever had," John receives nearly 100% of his engagements from referrals. His schedule is a testament to the power of his message and who he is as an individual. His emotional story-telling, unexpected humor and authenticity make each of his presentations truly transformational.

John is a two-time #1 National Bestselling author. His first book *ON FIRE: The 7 Choices to Ignite a Radically Inspired Life* has sold 250,000+ copies and been translated into 12 languages. I*N AWE: Rediscover Your Childlike Wonder to Unleash Inspiration, Meaning and Joy* published in May 2020 with many saying it is the message we all need right now.

John's award-winning *Live Inspired* Podcast has more than 2.5 million downloads and enjoys world-class guests like Brené Brown, Mitch Albom and Shawn Achor.

John considers his greatest success to be his marriage to his wife Beth, their four children and his relationships with friends and family.

Learning objectives:
After attending this presentation, attendees will be able to:

- Identify how changing the way they ask questions transforms the answers they receive – and the lives they lead
- Improve personal accountability for actions, attitudes and outcomes
- Better understand their impact within their team and re-ignite their passion for their profession

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

2021 State of the Union: The Resilient Healthcare System

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Ford Koles, Jr.
Bradford (Ford) is one of Advisory Board's preeminent thought leaders in the area of health system economics and strategy, and is the keynote speaker at the annual meetings for Advisory Board's strategy membership. He also leads the faculty for the company's Chief Executive Officer meeting series each year. Ford is a health care economist by training and has participated in every major Advisory Board research initiative since 1992. He is well-versed in healthcare history and the many reform initiatives we have lived through in the past three decades: coverage expansion; vertical integration and physician partnership models; managed care and payer contracting; horizontal integration and system economies of scale; and quality-based payment.

Prior to joining Advisory Board, he worked as a management consultant for both the Hay Group and Ernst & Young.

Ford received his BA from Kenyon College, and his MA in Economics from John Hopkins University.

Learning objectives:
After attending this presentation, attendees will learn:
- How health care purchasers and policymakers are shifting their strategies as a result of Covid-19
- How the pandemic is likely to impact provider consolidation and site-of-care shifts
- How the delivery system will need to shift operating models to enable greater resilience in the future

QuVa PHARMA

sponsored by

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

503As and The FDA: Understanding Sterile Compounding Laws and Policies

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Katrina K. Harper, PharmD, MBA, BCPS, BCSCP, DPLA

Katrina K. Harper, PharmD, MBA, BCPS, BCSCP, DPLA has more than 20 years of healthcare experience in several clinical and leadership roles. She is currently the Director of Pharmacy Services for AIS Healthcare's Ophthalmic Division. Prior to joining AIS Ophthalmics, she was the Clinical Pharmacy Director for the nation's largest member-driven, health care performance improvement company where she served as a subject matter expert in the areas of drug compounding, medication safety, regulations, quality, and compliance. Her previous experiences include being a Pharmacy Manager for a community pharmacy chain, Director of Pharmacy of a cardiovascular specialty hospital, and Medication Safety Officer for a safety-net academic county hospital. She has served as chairperson and adjunct faculty for an ASHP-accredited Pharmacy Technician program at a community college. Katrina is also a recipient of the Texas Society of Health-Systems Pharmacist's Larry C. Nesmith Pharmacist Recognition Award. She holds a Doctorate of Pharmacy degree from Xavier University of Louisiana College of Pharmacy and a Master's degree in Business Administration from the University of Texas at Arlington College of Business Administration. She is also a Board Certified Pharmacotherapy Specialist, a Board Certified Sterile Compounding Pharmacist and holds numerous other certifications.

Learning objectives:

After attending this presentation, attendees will learn to:

- Summarize FDA's oversight of traditional compounding pharmacies according to Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act
- Describe Insanitary Conditions at Compounding Facilities as defined by the FDA
- Summarize the FDA's policy on Compounding Drugs Using Bulk Drug Substances under Section 503A of the FD&C Act
- List interim guidance for industry by the FDA that may impact pharmacy practice

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

Confronting and Overcoming Bias in the Healthcare Industry

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Luther Wright, Jr. J.D., B.S.
After graduating from Vanderbilt University School of Law, Luther Wright, Jr. began his career with a general practice firm in the litigation section. He spent the first several years of his legal career practicing in the general litigation area before joining the Labor & Employment team. He has significant experience in the areas of labor and employment law, corporate business litigation and complex litigation, including class action and collective action lawsuits. He typically represents management in all forms of employment discrimination litigation, including litigation based on federal anti-discrimination statutes, state statutes and common law, violence in the workplace, Fair Labor Standards Act claims and independent contractor disputes. Luther is a member of Ogletree's Diversity and Inclusion Action Team that provides timely client advice and guidance on diversity related matters. Luther also devotes a significant amount of his practice to day-to-day client advice, general supervisor/employee training, training and advising on diversity and inclusion issues and workplace violence issues, and also acts as the Assistant Director of Client Training as part of the Ogletree Deakins Learning Solutions ("ODLS") team. ODLS provides employee and supervisor training in a variety of formats, including in-person training, training by webinar/webcasts and customized video training products.

Luther has experience representing banks, national gaming companies, automotive companies, government contractors, hospitals, restaurants, retail establishments, closely held businesses and entertainment companies in employment and business litigation. He has represented clients in litigation based on federal and state anti-discrimination laws, state tort litigation, personal injury matters involving commercial vehicles, claims under the Equal Credit Opportunity Act, class action and multi-plaintiff litigation.
He has practiced before Tennessee trial courts throughout the State of Tennessee, Federal District Courts in Alabama, Arkansas, Georgia, Illinois, Kentucky, Minnesota, New Mexico, Oklahoma, Tennessee and Wisconsin, and the United States Court of Appeals for the Sixth and Eleventh Circuits.

A highly evaluated public speaker, Luther has spoken before numerous industry groups, professional associations and clients across the country on topics ranging from implementation of employee discipline to respect in the workplace. His 1995 Law Review Article, Who's Black, Who's White and Who Cares: Reconceptualizing the United States' Definition of Race and Racial Classifications, 48 Vand. L. R.513 (1995) has been excerpted in more than 10 books and has been consistently cited in scholarly publications and textbooks since its publication.

Learning objectives:
After attending this presentation, attendees will learn to:
- Reveal unconscious biases
- Interrupt unconscious biases
- Address the issue of Microaggressions
- Develop strategies for improving cross-cultural communication and relationships organizationally and individually

Medicom Health

sponsored by

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

FDA Updates on 503B Compounding Policy and Quality



Co-presenter

Hidee L Molina, MS.

CDR Hidee Molina is a U.S. Public Health Service Commissioned Corps officer currently serving as the Branch Chief (acting) for Branch 1 within the Division of Compounding Quality (DCI), Office of Compounding Quality and Compliance (OCQC) in FDA's Office of Compliance. As a recognized authority in scientific and regulatory matters associated with pharmacy compounding, Molina oversees pharmacy compounding program's efforts to protect the American public from poor quality drug products and ensure compliance of firms with sections 503A and 503B of the Federal, Food, Drug and Cosmetic Act (FDCA). CDR Molina is a subject matter expert on sterile drug production and Current Good Manufacturing Practices (21 CFR 210 & 211).

She began her service with FDA on 2008 at the Office of Compliance in CDER as a compliance officer, where she evaluated regulatory compliance and generates enforcement actions of traditional human drug manufacturers. Prior to joining FDA, she worked for 7 years as a quality compliance specialist in several leading biotech drug manufacturing companies. She holds a BS and MS in Chemistry.



Co-presenter

Kemi Asante, PharmD, MPH, RAC

CDR Kemi Asante, PharmD, MPH, RAC is a U.S. Public Health Service Commissioned Corps officer currently serving as a Consumer Safety Officer (CSO) in FDA's Office of Compliance (OC), Office of Compounding Quality and Compliance (OCQC), Division of Compounding Policy and Outreach (DCPO). In this role, CDR Asante serves as a recognized authority in scientific and regulatory matters associated with pharmacy compounding. She develops and implements policies and compliance strategies to protect the public health by helping assure the quality of compounded drugs. She also evaluates bulk drug substances that have been nominated for use in compounding to determine eligibility for inclusion on FDA's Bulks List.

Prior to her current role, CDR Asante served as a CSO in OC's Office of Unapproved Drugs and Labeling Compliance (OUDLC) where she served as principal scientific advisor for case development, compliance strategies, and regulatory actions related to the inspection of compounding pharmacies nationwide. Prior to joining FDA, CDR Asante worked as a Clinical Pharmacist at the Johns Hopkins Hospital Inpatient Critical Care Pharmacy, MedStar Home Infusion Services and Bravo Health.

CDR Asante received her Doctorate in Pharmacy from Howard University, and Master of Public Health and Graduate Certificate in Global Health from UMass Amherst. She earned her Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society and U.S. Healthcare Compliance Certification from Seton Hall Law School. CDR Asante currently resides in Maryland with her husband and two beautiful daughters. She enjoys interior designing, loves to travel and appreciates the diverse cultures of the world.

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Continues on next page

KITCHECK

sponsored by

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

FDA Updates on 503B Compounding Policy and Quality

Continued from previous page

Co-presenter ***Q&A only***

Alexandria Fujisaki JD

Alexandria Fujisaki has worked as a Regulatory Counsel for the U.S. Food and Drug Administration (FDA) for eight years. During this time, Alexandria has focused on government contracts, tobacco products, and compounded human drug products. Currently, Alexandria leads several policy and legal initiatives on human drug compounding for the Office of Compliance within FDA's Center for Drug Evaluation and Research. Prior to joining FDA, Alexandria worked for the Rhode Island Office of the Attorney General where she focused on health law projects including hospital mergers and the Tobacco Master Settlement Agreement. Alexandria holds a Juris Doctor from the Catholic University of America Columbus School of Law.

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Learning objectives:

After attending this presentation, attendees will learn to:

- Recognize the statutory framework and requirements for 503B compounding
- Understand FDA's work on policy for hospitals and health system compounding
- Understand importance of quality as it relates to 503B compounding
- Understand 483s and responses

KITCHECK

sponsored by

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

Not everything is Covid-19: The History and Future for Prevention and Treatment of RSV and other similar Lower Respiratory Tract Viral Diseases

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Jerry Siegel Pharm.D.,FASHP

Jerry Siegel retired in 2009 as the Senior Director for Pharmaceutical Services for the Ohio State University Medical Center and Assistant Dean for the Ohio State University College of Pharmacy. He is still a clinical associate professor at the College of Pharmacy. He graduated from the Ohio State University with his B.S in microbiology and B.S. and Pharm.D. from the College of Pharmacy. Previously a clinical microbiologist he worked as a clinical pharmacist in transplantation and hematology/oncology before focusing on administration. He has had over 100 invited presentations and publications in the area of immunology and infectious disease. In 1995 he received the designation of Fellow of the American Society of Health-System Pharmacists. Dr. Siegel is the recipient of the 2011 American Society of Health System Pharmacists "Distinguished Leadership Award". Currently he is Vice President and managing partner of Safe Medication Management Associates Inc. (SMMA) consulting firm.

In 2014, Dr. Siegel was part of the team that received the ASHP/Cardinal National Safety Award and $50,000 grant at the ASHP midyear clinical meeting for the project at the Yale-New Haven Hospital on Telepharmacy. Dr.Siegel's focus recently has been designing and building pharmacy infusion centers and assuring and training staff compliance with USP <797> and <800> chapters. He has also provided lectures on the use of IVIG and Rabies immune globulin throughout the United States at state and local pharmacy associations. Most recently Dr. Siegel has been providing Covid-19 vaccinations at long term care facilities throughout Ohio as he is an APhA certified immunizer.

Learning objectives:

After attending this presentation, attendees will learn to:

- Distinguish the difference in symptoms of Covid-19 and other respiratory disease symptoms
- Distinguish the differences between Upper and Lower Respiratory tract diseases.
- Discuss the role of monoclonal antibodies in the prevention and treatment of LRTI
- Discuss the role of immune globulins in the prevention and treatment of LRTI
- Discuss the past, present and future state of vaccines in the prevention of RSV
- Discuss the impact of high-risk populations on the prevention strategies for LRTI

xellia PHARMACEUTICALS

sponsored by

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

Tackling Opioid Abuse in a Post-Pandemic Environment: Leveraging Artificial Intelligence to Identify the Pre-Diagnosed "Silent Majority"

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Dr Gidi Stein
CEO & Co-Founder, MedAware

Dr. Gidi Stein is an award-winning physician, researcher, technologist and an expert in medical informatics. Early in his career, he served as CTO and Chief Architect of several algorithm-rich startup companies in Israel. He uses his in-depth knowledge of these fields, researching the application of AI on electronic health records for practical clinical use at Tel Aviv University, where he is also a faculty member, teaching clinical medicine.

Dr. Stein received a PhD in Computational Biology from Tel Aviv University, the research for which focused on using computational methods on large-scale biological data for better prognostication of breast cancer patients. Dr. Stein has also published several data-driven manuscripts on cardiovascular topics such as heart failure, type-II myocardial infarction and the relevance of elevated troponin levels in an inpatient setting.

Dr. Stein is also a part-time senior physician at Meir Hospital, Israel, and CEO & Co-Founder of MedAware, which utilizes AI-driven outlier detection technology to mitigate medication-related risks and evolving adverse drug events.

Learning objectives:

After attending this presentation, attendees will learn:

- The impact of COVID-19 on opioid dependency, overdose and mortality
- How COVID-19 caused a loosening of Opioid Rx restrictions and a corresponding impact on opioid dependency
- Pros and cons of current decision support tools that identify opioid dependency and the role of personalized AI-based tools

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

Strategies for Complying with Challenging Joint Commission Medication Management Standards

Q&A Session 1
11:00am–11:15am CST

Q&A Session 2
5:00pm–5:15pm CST

Jeannell M. Mansur, R.Ph, Pharm.D, FASHP, FSMSO, CJCP
Principal Consultant, Medication Management and Safety
Joint Commission Resources
Joint Commission International

Jeannell Mansur is Principal Consultant for Medication Management and Safety for Joint Commission Resources and Joint Commission International. In this role, she provides direction to hospital leaders on medication safety design, medication system optimization and technology implementation to support patient safety and effectiveness. Her expertise in lean six sigma and change acceleration performance improvement methods and tools is of immense value to organizations that are seeking to implement effective and sustainable improvement to challenging issues. Also in her role as Principal Consultant, Dr. Mansur provides expertise to the Joint Commission enterprise on medication system themes. Dr. Mansur has been recognized for her distinguished work by the designation of Fellow with the American Society of Health-System Pharmacists and the American Society for Medication Safety Officers. She is a voting member of the United States Pharmacopeial (USP) Convention.

Dr. Mansur completed training with the Institute for Healthcare Improvement in medication safety under the direction of Drs. Donald Berwick and Lucian Leape. The learning from these leaders and the experiences from this Institute resulted in the crafting of a systems-based approach to medication safety that has molded Dr. Mansur's philosophies.

Dr. Mansur has extensive experience in all aspects of medication system design and implementation as well as hospital pharmacy which includes clinical, operational and management responsibilities. She was Director of Pharmaceutical Services for 12 years at the University of Chicago Medical Center before she became Executive Director for Pharmacy Informatics, where she was involved in the planning, building and implementation of the organization's electronic medical record.

Dr Mansur received her B.S. Pharmacy from the University of Michigan and her Doctor of Pharmacy degree from Wayne State University.

Learning objectives:

After attending this presentation, attendees will be able to:

- Describe changes in the Joint Commission medication standards and areas of focus for 2021
- Review trends in top challenging medication management (MM) standards and elements of performance
- Discuss strategies for implementing new allowances for complex orders
- Discuss top areas of focus for sterile compounding

Each session will be available for on-demand viewing (and Enduring CE) from Monday, April 12th until Friday, May 21st, but please keep in mind that we cannot provide Live CE credit unless you watched the session and participated in the Live Q&A for that session. Live Q&As are not available on-demand and will be available for Sessions 2-8 at the dates and times specified for each session.

BD

titlesponsor

Live! ONLINE nashville reverseexpo

8:00am–5:00pm CT daily

Session ONE
Tuesday April 27th

Session TWO
Wednesday April 28th

Session THREE
Thursday April 29th

Session FOUR
Tuesday May 4th

Session FIVE
Wednesday May 5th

Session SIX
Thursday May 6th

sponsored by

SCA pharma